Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY21 results · Jul–Sep 2020
Torrent Pharmaceuticals reported revenue from operations of ₹2,017.00 crore (up 0.6% from Q2 FY20) and net profit of ₹310.00 crore (up 27.0% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,017.00 | 2,005.00 | +0.6% | 2,056.00 | −1.9% |
| Other income | 6.00 | 34.00 | −82.4% | 4.00 | +50.0% |
| Total income | 2,023.00 | 2,039.00 | −0.8% | 2,060.00 | −1.8% |
| Profit before tax | 384.00 | 296.00 | +29.7% | 402.00 | −4.5% |
| Net profit for the period | 310.00 | 244.00 | +27.0% | 321.00 | −3.4% |
| EPS, basic (₹) | 18.32 | 14.48 | +26.5% | 18.98 | −3.5% |
| Net margin (%) | 15.4 | 12.2 | 15.6 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,640.00 | 1,603.00 | +2.3% | 1,727.00 | −5.0% |
| Other income | 9.00 | 123.00 | −92.7% | 7.00 | +28.6% |
| Total income | 1,649.00 | 1,726.00 | −4.5% | 1,734.00 | −4.9% |
| Profit before tax | 356.00 | 393.00 | −9.4% | 370.00 | −3.8% |
| Net profit for the period | 283.00 | 328.00 | −13.7% | 298.00 | −5.0% |
| EPS, basic (₹) | 16.68 | 19.40 | −14.0% | 17.63 | −5.4% |
| Net margin (%) | 17.3 | 20.5 | 17.3 |
Consolidated
- Filed with BSE
- 26 Oct 2020, 17:58 IST
- Board meeting
- 26 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Oct 2020, 17:58 IST
- Board meeting
- 26 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Audited
- Source
- XBRL filing on BSE